Physician profile
Crystal R Taylor
NPI 1376712893
$1,667.18
in general payments reported to CMS, 2019-2025
26 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $94.04 · 2023: $465 · 2024: $649 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.42 | 2022-2025 | |
| Novo Nordisk INC | $220.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $140.38 | 2024-2025 | Voquezna |
| Abbott Laboratories | $90.84 | 2021-2025 | Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $80.16 | 2023-2024 | Eliquis, Camzyos |
| Lilly USA, LLC | $71.18 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Insulet Corporation | $65.24 | 2024 | Omnipod |
| Janssen Biotech, INC. | $61.85 | 2023-2024 | Tremfya |
| Glaxosmithkline, LLC. | $54.80 | 2022-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $51.44 | 2023-2024 | Farxiga, Airsupra |
| Tandem Diabetes Care, INC. | $47.86 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $44.99 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $44.89 | 2023-2024 | |
| Pfizer INC. | $41.90 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.11 | 2024 | Jardiance, Tradjenta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31.76 | 2021 | |
| Lundbeck LLC | $28.23 | 2023-2024 | Rexulti |
| Medtronic, INC. | $23.17 | 2025 | Minimed 780g |
| Recor Medical INC | $21.35 | 2025 | Paradise Ultrasound Renal Denervation System |
| Astellas Pharma US INC | $20.67 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.85 | 2023 | Xifaxan |
| Alkermes, INC. | $18.65 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $17.74 | 2023 | Imcivree |
| Averitas Pharma INC. | $16.20 | 2023 | Qutenza |
| Exact Sciences Corporation | $16.05 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.